A novel 4-gene signature for overall survival prediction in lung adenocarcinoma patients with lymph node metastasis.

In summary, we developed a robust mRNA signature as an independent factor to effectively classify LUAD patients with LNM into low- and high-risk groups, which might provide a basis for personalized treatments for these patients.